Medigus today announced the completion of a live transoral fundoplication (TF) procedure using the Medigus Ultrasonic Surgical Endostapler (MUSE™) system.
Medigus Ltd. today announced that it has entered into a definitive agreement with institutional investors providing for the issuance of 1,139,170 American depositary shares (ADS) at a purchase price per ADS of $0.67 in a registered direct offering.
Medigus Ltd. announced today that it has received a Notice of Intention to Grant a Patent from the European Patent Office (EPO) for its micro ScoutCam™ miniature camera technology.
Medigus Ltd. today announced financial results for the third quarter ended September 30, 2016.
Medigus entered into definitive securities purchase agreements with two institutional investors.
Medigus Ltd. today announced financial results for the second quarter ended June 30, 2016.
World renowned healthcare institution purchases its first MUSE console and device to offer GERD patients a minimally-invasive treatment option
Innovative technology allows physicians to perform transoral fundoplication for effective, long-term treatment of acid reflux and improve patients’ GERD-related quality of life
Physicians can benefit from the latest technological advancements in microvisual, ultrasonic and endostapling to perform transoral fundoplication more effectively with the latest generation of the MUSE system
Medigus Ltd. today announced financial results for the first quarter ended March 31, 2016.
Study results being presented during Digestive Disease Week® (DDW) 2016